Using a unique resource of samples from a controlled human malaria infection (CHMI) study, we identified a novel population of CD4 + T cells whose frequency in the peripheral blood was inversely correlated with parasite burden following P. falciparum infection. These CD4 + T cells expressed the multifunctional ectoenzyme CD38 and had unique features that distinguished them from other CD4 + T cells. Specifically, their phenotype was associated with proliferation, activation and cytotoxic potential as well as significantly impaired production of IFN-γ and other cytokines and reduced basal levels of activated STAT1. A CD38 + CD4 + T cell population with similar features was identified in healthy uninfected individuals, at lower frequency. CD38 + CD4 + T cells could be generated in vitro from CD38 -CD4 + T cells after antigenic or mitogenic stimulation. This is the first report of a population of CD38 + CD4 + T cells with a cytotoxic phenotype and markedly impaired IFN-γ capacity in humans.
+ T cell population with similar features was identified in healthy uninfected individuals, at lower frequency. CD38 + CD4 + T cells could be generated in vitro from CD38 -CD4 + T cells after antigenic or mitogenic stimulation. This is the first report of a population of CD38 + CD4 + T cells with a cytotoxic phenotype and markedly impaired IFN-γ capacity in humans.
The expansion of this CD38 + CD4 + T population following infection and its significant association with reduced blood-stage parasite burden is consistent with an important functional role for these cells in protective immunity to malaria in humans. Their ubiquitous presence in humans suggests that they may have a broad role in host-pathogen defense.
Trial Registration
ClinicalTrials.gov clinical trial numbers ACTRN12612000814875, ACTRN12613000565741 and ACTRN12613001040752
Introduction
Malaria is associated with complex multi-factorial immune responses, due in part to the multistage life cycle of the Plasmodium spp. parasite which is targeted by multiple arms of the immune system, and the existence of elaborate host-pathogen interactions and evasion mechanisms [1] . The effector cells and immune mediators contributing to protection against the sporozoite, liver, and blood-stages of malaria have been the subject of intense investigation over many years [2] [3] [4] , but the specific molecular mechanisms and critical effector cells that mediate control of parasite burden remain largely unknown [1, 3, 5] . CD4 + T cells have been implicated in the control of blood-stage parasitemia in numerous animal models [6] ; and in humans an association with parasite control has been demonstrated in studies utilizing CHMI [7, 8] . An important effector function of CD4 + T cells is the production of various pro-and anti-inflammatory cytokines including IFN-γ, IL-2, IL-4, IL-10, IL-17 and TNF [9] . In blood-stage malaria, IFN-γ has been implicated as the key cytokine driving effective immune responses [10] , and circumstantial evidence associates CD4 + T cells producing IFN-γ with protection against P. falciparum blood-stage infection in humans [7, 8] . CD4 + T cells expressing the degranulation marker CD107a have been identified in circulating PBMCs from subjects protected by immunization with P. falciparum sporozoites under the cover of chloroquine chemoprophylaxis following in vitro stimulation with P. falciparum-infected red blood cells [11] . Cytolytic CD4 + T cells have also been described as potent immune effectors in protection against many viral infections, including CMV, Epstein-Barr Virus, Influenza and HIV [12] [13] [14] .
In humans, recently activated T cells are typically identified ex vivo via the upregulation of cell surface glycoproteins such as CD69 or CD38 [15] . CD69 is one of the earliest molecules detected on the T cell surface following TCR engagement, and CD69 mediated signaling results in a range of cellular responses including proliferation [16] . CD38 is expressed on the surface of immature but not mature hematopoietic cells, and is also re-expressed by many immune cells (including CD4 + T cells) after activation [17, 18] . Circulating T cells expressing CD38 during infection have been associated with a recently activated effector phenotype [19, 20] ; and antigen-specific CD4 + T cells have been shown to express high levels of CD38 and produce IFN-γ in the acute phase of several viral infections including EBV [21] , HIV [22] and Influenza [23] . CD38 is a multifunctional molecule that acts as an ectoenzyme to catalyze the conversion of NAD + to the second-messenger cyclic-ADB-ribose (cADPR) and is considered the major regulator of intracellular and extracellular NAD + levels [24] . The purpose of CD38 signaling in T cell immunity is not fully elucidated, although there is strong evidence that the products of CD38 enzymatic activity (principally cADPR) enhance intracellular calcium mobilization which is required for a multitude of cell functions including lymphocyte proliferation [25] and lymphocyte migration [26, 27] . Signaling through CD38 has also been reported to promote the activation and cytotoxic function of human NK cells [28, 29] . Experimental infection models provide an excellent opportunity to investigate the mechanisms underlying the induction of immunity following primary exposure of the human immune system to target pathogens. Here, we utilized a model of controlled human malaria infection (CHMI) of naive healthy volunteers [30-32] to explore the mechanisms underlying the induction of T-cell-associated immunity in blood-stage malaria. We show that the levels of parasite burden following experimental P. falciparum blood-stage infection inversely correlated with the expansion of a specific subset of CD4 + T cells expressing CD38 and characterized by high cytotoxic potential but impaired cytokine production. These cells were also present at lower frequency in healthy uninfected individuals, and could be generated in vitro from CD38 -CD4 + T cells after antigenic or mitogenic stimulation.
Results
Control of parasite burden following first-exposure to P. falciparum correlates with the expansion of CD38 + CD4 + T cells
To determine whether significant changes could be detected in the phenotype of circulating lymphocytes following infection, the frequencies of T cells and B cells expressing the activation markers CD69 or CD38 were measured prior to and seven days post-infection with P. falciparum. In all volunteers, infection led to a significant increase in the frequency and absolute numbers of CD69 + T cells and B cells ( Fig 1A and S1 Fig) + or CD38 + T cells and B cells circulating during infection and parasite burden. Statistical differences between cell frequencies pre-and postinfection were determined using the non-parametric Wilcoxon test; box and whisker plots indicate median, interquartile range and min-max. Univariate regression analysis was performed with R, and p values adjusted for multiple comparisons using the Bonferroni method. Graphs show combined data from 22 volunteers from five independent cohorts. **, p < 0.01; ***, p < 0.001.
that a greater proportion of CD38 + CD4 + T cells expressed CD45RA in comparison to CD38 -CD4 + T cells both prior to, and at peak infection (Fig 2A and 2B) -(black) or CD38 + (red) CD4 + T cells freshly isolated from volunteers prior to and seven days post infection after brief stimulation with platebound anti-human CD3 antibody. Graphs show combined data from (A-F) 22 volunteers from five independent cohorts, (G-I) 13 volunteers from two independent cohorts, (J-K) seven volunteers from one cohort. Statistical differences between CD38 -and CD38 + CD4 + T cells or between pre-and post-infection were determined using the non-parametric Wilcoxon test; box and whisker plots indicate median, interquartile range and min-max; *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001 ns, p > 0.05. -and CD38 + CD4 + T cells or between pre-and post-infection were determined using the non-parametric Wilcoxon test; box and whisker plots indicate median, interquartile range and min-max; *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001. (Fig 5E) , the levels of pSTAT5 were similar between CD38 + and CD38 -CD4 + T cells (Fig 6A and 6B) , suggesting that both cells subsets retain similar capacity to respond to IL-2. Upon infection, the levels of pSTAT1 and pSTAT4 within both CD38 + and CD38 -CD4 + T cells decreased (Fig 6C) , while the expression of pSTAT5 was significantly decreased in the CD38 + CD4 + T cell subset only (Fig 6C) . + and CD38 -CD4 + T cells and between prior to and seven days post infection were determined using the non-parametric Wilcoxon test; box and whisker plots indicate median, interquartile range and min-max; *, p < 0.05, **, p < 0.01; ***, p < 0.001; ****, p < 0.0001. doi:10.1371/journal.ppat.1005839.g005
Cytotoxic CD38 + CD4 + T Cells with Impaired IFN-γ Differences in the basal levels of pSTAT1 between the two CD4 + T cell subsets were not due to differences in total STAT1 protein as there was no apparent difference in the levels of intracellular STAT1 between CD38 -and CD38 + CD4 + T cells (Fig 6D) .
In order to determine whether the observed differences in basal levels of pSTAT1 were due to variation in cytokine responsiveness, we assessed the phosphorylation levels of STAT1 in CD38 + and CD38 -CD4 + T cells isolated from healthy uninfected volunteers following in vitro exposure to IFN-γ or IFN-α. In both cell subsets, a 15 min exposure to IFN-γ induced a small but insignificant increase in phosphorylation of STAT1 (Fig 6E) . However, IFN-α exposure induced significant phosphorylation of STAT1 (both p = 0.0313, with non-parametric Wilcoxon test) and brought the levels of pSTAT1 to similar levels in the CD38-and CD38 + subsets (Fig 6E) , indicating a similar responsiveness to IFN-α and ability to phosphorylate STAT1 and excluding a specific defect in the ability of CD38 + T cells to phosphorylate STAT1. -and CD38 + CD4 + T cells and between prior to and seven days post infection were determined with the non-parametric Wilcoxon test; box and whisker plots indicate median, interquartilerange and min-max. Graphs show combined data from (A-C) seven volunteers from one cohort (pre) and 13 volunteers from two separate cohorts (post), (D-E) six healthy controls. *, p < 0.05; ***, p < 0.001 ns, p > 0.05. (Fig 7A and 7B) . Similar to the CD38 + CD4 + T cells circulating in vivo in the P. falciparum experimental infection model, this in vitro generated CD38 + CD4 + T cell population showed a phenotype associated with recent activation (Fig 7C and 7D) and cytotoxic potential at both protein (Fig 7E and 7F ) and mRNA levels ( Fig 7G) . contributing to protection against pathogens with a tropism for MHC-II expressing cells [9, 12] . However, since red blood cells lack MHC-II molecules, so the mechanism by which CD38 + CD4 + T cells could exert their cytotoxic function in blood-stage malaria remains to be elucidated. One possibility is that the cells might be operating through a MHC-independent mechanism, as observed in NK cells [50] . Alternatively, the cytolytic CD38 + CD4 + T cells might be responsible for MHC-II dependent killing of recently activated antigen presenting Cytokine production by T cells is highly modulated during T cell differentiation, notably through epigenetic modifications [59] [60] [61] . Thus, it is possible that in vivo the upregulation of CD38 by CD4 + T cells is accompanied by epigenetic changes that inhibit the transcription of genes coding for cytokines. Thus, we speculate that the analysis of epigenetic modifications to cytokine promoters in circulating CD38 + CD4 + T cells in the context of natural or experimental infection will inform the molecular mechanisms controlling cytokine production within this cell population.
Although an increase in frequency of circulating CD38 + CD4 + T cells has been observed following immunization or infection in a number of host-pathogen systems [20, 23, 62] , the role of those cells has not been elucidated, and impaired cytokine capacity has not been reported. All volunteers in our CHMI study had a pre-existing proportion of CD4 + T cells expressing CD38 prior to infection, as do all healthy volunteers we have since examined. All CD38 + CD4 + T cells isolated from healthy volunteers either prior to infection, or during experimental malaria infection, displayed similar features clearly distinguishing them from CD38 -CD4 + T cells. Taken together, these results lead us to speculate that this cell population might also expand during other infections. This could explain the variation observed in the pre-existing proportion of CD38 + cells among total CD4 + T cells between individuals (ranging from 0.9 to 10.9% of total CD4 + T cells), reflecting a more or less recent infection with a pathogen. This idea is also supported by the recent study from Tsang et al, which highlighted that the proportion of CD4 + T cells expressing CD38 was a feature presenting very high inter-individual variability [63] .
In conclusion, we have identified a unique population of circulating CD38 + CD4 + T cells in humans with characteristics that clearly distinguish them from other CD4 + T cells; specifically, markers of recent activation and cytotoxic potential but impaired cytokine production. This CD4 + T cell population was specifically expanded in experimental blood-stage malaria infection and was significantly associated with reduced parasite burden. This is consistent with a critical role for these cells in protective immunity to malaria. Further insights into the function and origin of this cell population might provide novel immune correlates of protection in blood-stage malaria and other infectious diseases, and inform vaccine design.
Material and Methods

Ethics statement
Experimental infection of malaria-naive healthy adult volunteers was undertaken at QPharm Pty Ltd (Brisbane, Australia) with approval of the QIMR Berghofer Medical Research Institute Human Research Ethics Committee (QIMRB-HREC) and Medicines for Malaria Venture (MMV). Clinical studies were registered on the Australian and New Zealand Clinical Trials Registry (ANZCTR): clinical trial numbers ACTRN12612000814875, ACTRN12613000565741 and ACTRN12613001040752. All subjects were enrolled with written informed consent.
Samples from P. falciparum experimentally infected volunteers
Inoculum preparation, volunteer recruitment, infection, monitoring and treatment were performed as described previously [64] . In brief, healthy malaria-naive individuals were intravenously inoculated with 1,800 viable P. falciparum parasitized erythrocytes, and treated with anti-malarial drugs at seven to eight days post-infection. Blood samples were collected prior to infection and seven days post-infection (before anti-malarial drug treatment). Peripheral blood from healthy volunteers was also collected under informed consent and approval by the QIMRB-HREC. Peripheral blood collected in Lithium Heparin Vacutainers (BD Biosciences) was either used directly for flow cytometry analysis, or peripheral blood mononuclear cells (PBMC) isolated using standard Ficoll density gradient centrifugation.
Determination of parasite burden in P. falciparum experimentally infected volunteers
Parasitemia levels over the course of the infection were determined using a consensus P. falciparum species-specific quantitative PCR assay from 500 μl of packed red blood cells as previously described [65] . Parasite levels were assessed once daily until day four post-infection and then twice daily until treatment. All samples were batch tested in triplicate together after each study completion. The total parasite burden across the first seven days of infection was defined as the area under the curve of the transformed parasite levels from day 0 to day 7 of infection using the trapezoidal rule. The limit of detection was 64 parasites/500 μl packed red blood cells [65] .
Flow cytometry antibodies and staining buffer
Details about the clones, manufacturers and optimum dilutions for each antibody used in this study are listed in S1 Table. Unless otherwise stated, staining buffer was a PBS solution supplemented with 0.5% FCS and 4 mM EDTA and filtered through 0.2 μm.
Flow cytometric analysis from whole blood
Whole blood collected in Lithium Heparin vacutainers was lysed and fixed with BD FACS lysing solution (BD Biosciences) and lymphocytes permeabilized with BD FACS permeabilizing solution 2 (BD Biosciences) according to the manufacturer's instructions. Cells were then resuspended in 50 μl of staining buffer containing surface and intracellular antibodies at previously determined optimum dilution along with 1 μl of human Fc receptor blocking solution (Human TruStain FcX, Biolegend) for 30 mins at room temperature, washed and resuspended in staining buffer. Samples were acquired using a LSR Fortessa 4 (BD Biosciences) with Diva software, and analyzed using FlowJo software (version 6.0).
Flow cytometric analysis from PBMC and sorted CD4 + T cells
Approximately 5x10 
Phosphoflow on whole blood
200 μl of whole blood was stained with anti-human CD4-BV510, anti-human CD8-APC-H7 and anti-human CD38-APC at previously determined optimum dilution for 15 mins at 37°C with or without recombinant human IFN-α2 (Biolegend) or recombinant human IFN-γ (ProSpec) at 100 ng/mL. Whole blood was lysed and fixed with Phosflow Lyse/fix 1x solution (BD Biosciences) and lymphocytes permeabilized with BD Perm III solution (BD Biosciences) according to the manufacturer's instructions. Cells were then resuspended in 50 μl of staining buffer containing anti-human pSTAT1-PECF594, anti-human pSTAT4-AF488 and antihuman pSTAT5-PE at previously determined optimum dilution for one hour at room temperature. Cells were washed and resuspended in staining buffer. Samples were acquired using a LSR Fortessa 4 (BD Biosciences) with Diva software, and analyzed using FlowJo software (version 6.0). Gene expression on ex vivo or in vitro stimulated sorted cells RNA was extracted from sorted CD38 + and CD38 -CD4 + T cells directly ex vivo by resuspending the cells directly in RLT buffer or after in vitro stimulation to induce cytokine production. For the in vitro stimulation assay, sorted cells were plated at 50,000 cells/well in RPMI 1640 containing 25 mM Hepes, 2 mM L-glutamine (Invitrogen), and supplemented with 10 units/ mL of Penicillin (Life Technologies), 10 μg/mL of Streptomycin (Life Technologies) and 10% fetal bovine serum (Life Technologies) and stimulated with 5 ng/mL of phorbol myristate acetate PMA (Sigma Aldrich) and 500 ng/mL Ionomycin (Sigma Aldrich) for 5h at 37°C in an atmosphere of 5% C0 2 . Following stimulation, supernatants were harvested, cell pellets resuspended in RLT buffer and stored at -70°C. On the day of extraction, frozen cell lysates were thawed quickly on ice and mRNA was extracted using the RNEasy micro kit (Qiagen) according to the manufacturer's instructions. cDNA was synthesized using oligo-dT and Superscript III RT (Invitrogen) according to the manufacturer's instructions. Eomes, Granzyme B, Granzyme A, Granzyme K, IFN-γ, IL-2, IL-4, IL-10, IL-17A, Perforin, RPL13A, and TNF gene expression were measured from 1 μl of cDNA (or pre-amplified cDNA) using individual Taqman gene expression assays (Life Technologies) and Platinum Taq polymerase (Life technologies) in a 10 μl volume reaction on a 384-well plate using the Light Cycler 480 real time PCR cycler (Roche) according to the manufacturer's instructions. Each gene expression was assayed in duplicate. Cycling conditions used were: 50°C for 2 mins followed by 95°C for 10 mins, 40 cycles at 95°C for 15 secs and 60°C for 1 min. Fold changes were calculated with the ddCt value method [66] using RPL13A expression as the reference gene, and the expression values from the unstimulated cells as baseline. 
Cell sorting
TCR stimulation assay on sorted cells
Sorted CD38 + and CD38 -CD4 + T cells were plated at 50,000 cells/well in RPMI 1640 containing 25 mM Hepes, 2 mM L-glutamine, and supplemented with 10 units/mL of Penicillin, 10 μg/mL of Streptomycin and 10% fetal bovine serum in a 96-well plate pre-coated overnight with 10 μg/mL of anti-human CD3 OKT3 antibody (Biolegend) and incubated for 5 h at 37°C in an atmosphere of 5% C0 2 . Following stimulation, cells were resuspended in 20 μl of staining buffer containing anti-human CD4-BV510, anti-human CD8-APC-H7, anti-human CD69-AF700 at previously determined optimum dilution for 20 mins at 4°C, washed and resuspended in staining buffer before acquisition on LSR Fortessa 4 (BD Biosciences) with Diva software. FlowJo version 6.0 was used for gating.
In vitro generation of CD38 + CD4 + T cells
Sorted CD38 -CD4 + T cells from healthy uninfected volunteers were plated at 0.5x10 6 cells/well in RPMI 1640 containing 25 mM Hepes, 2 mM L-glutamine, supplemented with 10 units/mL of Penicillin, 10 μg/mL of Streptomycin and 5% human AB serum (Sigma Aldrich) and stimulated with P. falciparum parasitized red blood cells extract at 1x10 6 pRBC/ml or PHA at 5 μg/ mL (Sigma Aldrich) for six days at 37°C in an atmosphere of 5% C0 2 . Following stimulation, cells were either used directly for flow cytometric analysis, or further sorted into CD38 + and CD38 -cells for in vitro stimulation and gene expression analysis as described above.
Statistical analysis
Statistical analyses were performed using GraphPad Prism Software (version 6). Normality was assessed using D'Agostino and Pearson Omnibus normality test and showed the datasets were not normally distributed. Therefore, all paired datasets were compared using the non-parametric Wilcoxon test. All univariate and multivariate analysis were performed with R. Univariate analysis was performed with a linear regression analysis and p values were adjusted for multiple comparisons using the Bonferroni method. Multivariate analysis was performed with a multivariate linear regression analysis with forward stepwise covariate selection using Akaike information criteria. P values less than 0.05 were considered as significant. 
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